articleTop 1% cited

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

The Lancet Oncology · 2016 · Vol. 17(7) · pp. 956–965

Tanguy Y. Seiwert✉(University of Chicago)Barbara Burtness(Fox Chase Cancer Center)Ranee Mehra(Fox Chase Cancer Center)Jared Weiss(University of North Carolina at Chapel Hill)Raanan Berger(Sheba Medical Center)Joseph P. Eder(Yale Cancer Center)Karl Heath(Merck & Co., Inc., Rahway, NJ, USA (United States))Terrill K. McClanahan(Merck & Co., Inc., Rahway, NJ, USA (United States))Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States))Christine K. Gause(Merck & Co., Inc., Rahway, NJ, USA (United States))Jonathan D. Cheng(Merck & Co., Inc., Rahway, NJ, USA (United States))Laura Q.M. Chow(University of Washington)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers Head and Neck Cancer Studies Peptidase Inhibition and AnalysisMedicinePembrolizumabTolerabilityInternal medicineHead and neck squamous-cell carcinomaOncologyResponse Evaluation Criteria in Solid TumorsAdverse effectHead and neck cancerPopulation

MeSH terms

AdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellFemaleFollow-Up StudiesHead and Neck NeoplasmsHumansLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosis

Citations

1,718

FWCI

102.91

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Journal of Clinical Investigation · 2017 · 3,763 citations